HEALTH-RELATED QUALITY OF LIFE (HRQoL) ASSESSMENT FOLLOWING RADICAL CYSTECTOMY IN POPULATION OF A SOUTH ASIAN COUNTRY
Purpose: Radical cystectomy is carried out for muscle invasive bladder (BL) cancer, which greatly affects the quality of life. The objective of our study was to assess the health-related quality of life (HRQoL) in patients following radical
Methods: A retrospective review was done in patients that underwent radical cystectomy between July 2009 and November 2014 at Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Pakistan. HRQoL
assessments of 34 patients done during clinical psychology review were included in this study. HRQoL was assessed using functional assessment of cancer therapy-BL questionnaire.
Results: Low scores were observed in physical well-being and emotional well-being domains with mean scores of 7.32 and 7.97, respectively. Patients scored high on social and family well-being, functional well-being and additional
concerns, with mean scores of 24.9, 17.24 and 21.73, respectively.
Conclusions: Psychological evaluation and rehabilitation should be an integral part of surveillance after radical cystectomy.
Key words: Bladder cancer, functional assessment of cancer therapy-bladder, health-related quality of life, radical
cystectomy, South Asian
Zietman AL, Sacco D, Skowronski U, et al. Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: Results of a urodynamic and quality of life study on long-term survivors. J Urol 2003;170:1772-6.
Roca JF. Bladder preservation protocols in the treatment of muscle invasive bladder cancer. Cancer Control 2004;11:358-63.
Testa MA, Simonson DC. Assessment of quality-of-life outcomes. N Engl J Med 1996;334:835-40.
Shih C, Porter MP. Health-related quality of life after cystectomy and urinary diversion for bladder cancer. Adv Urol 2011;2011:5.
Park J, Ahn H. Radical cystectomy and orthotopic bladder substitution using ileum. Korean J Urol 2011;52:233-40.
Winters BR, Wright JL, Holt SK, et al. Health related quality of life following radical cystectomy: Comparative analysis from the medicare health outcomes survey. J Urol 2018;199:669-75.
Månsson A, Månsson W. When the bladder is gone: Quality of life following different types of urinary diversion. World J Urol 1999;17:211-8.
Yuh B, Butt Z, Fazili A, et al. Short-term quality-of life assessed after robot-assisted radical cystectomy: A prospective analysis. BJU Int 2009;103:800-4.
Palapattu GS, Haisfield-Wolfe ME, Walker JM, et al. Assessment of perioperative psychological distress in patients undergoing radical cystectomy for bladder cancer. J Urol 2004;172:1814-7.
Kulaksizoglu H, Toktas G, Kulaksizoglu IB, et al. When should quality of life be measured after radical cystectomy? Eur Urol 2002;42:350-5.
Hart S, Skinner EC, Meyerowitz BE, et al. Quality of life after radical cystectomy for bladder cancer in patients with an ileal conduit, cutaneous or urethral kock pouch. J Urol 1999;162:77-81.
El-Sayed M, El-Azab A, El- Gammal M. Quality of life in bladder cancer patients treated with radical 12. cystectomy and orthotopic bladder reconstruction versus bladder preservation protocol. J Cancer Sci Ther 2013;5:190-3.
Hobisch A, Tosun K, Kinzl J, et al. Quality of life after cystectomy and orthotopic neobladder versus ileal conduit urinary diversion. World J Urol 2000;18:338-44.
Dutta SC, Chang SC, Coffey CS, et al. Health related quality of life
assessment after radical cystectomy: Comparison of ileal conduit with continent orthotopic neobladder. J Urol 2002;168:164-7.
Autorino R, Quarto G, Di Lorenzo G, et al. Health related quality of life after radical cystectomy: Comparison of ileal conduit to continent orthotopic neobladder. Eur J Surg Oncol 2009;35:858-64.
Kikuchi E, Horiguchi Y, Nakashima J, et al. Assessment of long-term quality of life using the FACT-BL questionnaire in patients with an ileal conduit, continent reservoir, or orthotopic neobladder. Jpn J Clin Oncol 2006;36:712-6.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Authors retain copyright and grant the Journal of Cancer & Allied Specialties (JCAS) right-of-first publication. In addition, the work will be simultaneously licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International license. This license allows others to share the work in whole or part (for non-commercial purpose), with an acknowledgement of the work’s authorship and initial publication in JCAS.
Furthermore, authors are free to enter into separate contractual arrangements for the non-exclusive distribution of the journal’s published version of the work, with an acknowledgement of its initial publication in this journal.
Authors are permitted and encouraged to share their work online or in medical or scientific conferences prior to or during submission process.